- ACADIA (ACAD) got EMA CHMP positive opinion for trofinetide (Daybue) for Rett syndrome; European Commission decision due in months. Shares jumped about 13% premarket to ~$27.30.
- ACADIA Pharmaceuticals says a Daybue approval would grant marketing authorization across the EU plus Iceland, Liechtenstein and Norway, enabling commercialization in those markets.
TradingView
Key facts: ACADIA CHMP nod for Daybue; would cover EU plus 3 countries
ACADIA (ACAD) got EMA CHMP positive opinion for trofinetide (Daybue) for Rett syndrome; European Commission decision due in months. Shares jumped about 13% premarket to ~$27.30.ACA